Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: GlaxoSmithKline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline

4Q Revenues: $10.3 billion (+13%)

4Q Earnings: $1.9 billion (+45%)

FY Revenues: $37.8 billion (+8%)

FY Earnings: $8.2 billion (+20%)

Comments: Growth driven by key products: Seretide/Advair, Avandia and the company’s vaccines business. Sales of Seretide/Advair rose 22% to $5.2 billion and sales of Avandia rose 18% to $2.3 billion for the year. The company’s vaccines business posted total sales of $2.4 billion, up 15%, led by Infanrix vaccine. The company expects to file for approval for its cervical cancer vaccine, Cervarix, in the EU in March and in the U. S. before the end of the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters